Illumina Inc.

(NasdaqGS:ILMN)
Life Sciences Tools and Services Employees: 2,200 Incorporated: 1998 in Delaware, US 5200 Illumina Way San Diego, California 92121 United States Phone: 858-202-4500 www.illumina.com Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Its sequencing platforms include HiSeq 2000, an instrument for high-throughput sequencing using sequencing-by-synthesis (SBS) technology; HiSeq 1000 that accommodates lower throughput needs; MiSeq, a personal sequencing system that offers sequencing applications in a compact and economical instrument for individual researchers; and Genome Analyzer IIx. The company’s sequencing/array combination platforms comprise HiScanSQ that combines SBS technology and HiScan microarray analysis instrumentation into one...

Key Statistics
12 Months Jan-03-2010A Total Revenue Growth Over Prior Year Gross Profit Margin % EBITDA Margin % EBIT Margin % Net Income Margin % Diluted EPS Excl. Extra Items Diluted EPS Excl. Extra Items... 666.32 16.2% 69.1% 25.8% 21.1% 10.8% 0.53 76.7% 12 Months Jan-02-2011A 902.74 35.5% 67.5% 27.8% 23.2% 13.8% 0.87 64.2% 12 Months Jan-01-2012A 1,055.54 16.9% 68.3% 30.8% 24.3% 8.2% 0.62 (28.7%) 12 Months Dec-31-2012E 1,133.13 1.46 12 Months Dec-31-2013E 1,223.03 1.68 -

EPS Estimate (USD)

Estimates
Recommendation TargetPrice LT Growth Outperform(2.45) 56.00 16.73%

Revenue by Business and Geographic Segments (USD, mm)

Forward Multiples
FY2012 P/E TEV/REV TEV/EBITDA PEG 32.26x 4.80x 14.85x 1.93x FY2013 28.06x 4.44x 13.11x 1.68x

Competitors - NTM TEV/Fwd EBITDA
* Segments with negative values, such as corporate eliminations, are excluded from the total and percentage calculations and do not appear on the charts

Top Holders
Holder Capital Research and Management Company Baillie Gifford & Co. Sands Capital Management, LLC Morgan Stanley, Investment Banking and... Morgan Stanley Investment Management Inc.
Holders as of Friday, April 13, 2012

Common Stock Equivalent Held 13,975,676 13,690,903 11,122,866 9,317,417 9,154,978

% of Total Shares Market Value (USD Outstanding in mm) 11.34 11.11 9.03 7.56 7.43 691.9 677.8 550.7 461.3 453.3

Capitalization
Share Price as of Apr-12-2012 Shares Out. Market Capitalization - Cash & Short Term Investments + Total Debt + Pref. Equity + Total Minority Interest = Total Enterprise Value (TEV) Book Value of Common Equity + Pref. Equity + Total Minority Interest + Total Debt = Total Capital 49.51 123.25 6,101.86 1,189.57 807.37 5,719.66 1,075.22 807.37 1,882.58

Market Data
Last (Delayed Quote) Open Previous Close Change Change % Day High/Low 52 wk High/Low Volume (mm) Avg. Vol - 3 mo (mm) 47.17 Market Cap (mm) 49.95 Shares Out. (mm) 47.17 Float % (2.34) Shares Sold Short... (4.7%) Dividend Yield % 49.9/46.5 Diluted EPS Excl.... 79.4/25.5 P/Diluted EPS Before... 9.58 Beta 3.29 5,813.5 123.2 98.7% 25.4 0.62 76.08x 0.55

Share Price & Volume (USD)

Key Executives and Board Members
Rastetter, William H. Flatley, Jay T. Walt, David R. Stapley, Marc Bonnar, William Non Executive Chairman, Member of Nominating &... Chief Executive Officer, President and Director Founder, Chairman of Scientific Advisory Board,... Chief Financial Officer, Senior Vice President and... Senior Vice President of Operations

Events
Date/Time Apr-18-2012 Apr-23-2012 May-07-2012 Event Annual General Meeting Estimated Earnings Release Date (CIQ Derived) Conference

Date Created: Apr-13-2012

Historical Equity Pricing Data supplied by